Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Carroll

Showing results (91-100 of 126) with videos related to

Pageof 13
Sort By:
The Journal of Clinical Investigation|May 7, 2024
A mitochondrial surveillance mechanism activated by SRSF2 mutations in hematologic malignanciesXiaolei Liu, Sudhish A Devadiga, Robert F Stanley, et al.
Haematologica|March 10, 2018
Dexamethasone in hyperleukocytic acute myeloid leukemiaSarah Bertoli, Muriel Picard, Emilie Bérard, et al.
Blood|June 2, 2021
Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemiaCaroline Duault, Anil Kumar, Adeleh Taghi Khani, et al.
Blood|September 7, 2007
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsMonica L Guzman, Randall M Rossi, Sundar Neelakantan, et al.
Cancer Cell|February 23, 2010
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutaratePatrick S Ward, Jay Patel, David R Wise, et al.
Leukemia|January 5, 2024
FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemiaPamela J Sung, Murugan Selvam, Simone S Riedel, et al.
Plos One|October 26, 2020
Targeted detection and quantitation of histone modifications from 1,000 cellsNebiyu A Abshiru, Jacek W Sikora, Jeannie M Camarillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemiaDonald E Tsai, Selina M Luger, Charalambos Andreadis, et al.
Cancer Discovery|January 27, 2021
Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML RecurrenceCihangir Duy, Meng Li, Matt Teater, et al.
European Journal of Haematology|December 27, 2024
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based RegimenMargaret Rowe, Daria Babushok, Martin Carroll, et al.
Pageof 13

Showing results (91-100 of 126) with videos related to

Sort By:
Pageof 13
The Journal of Clinical Investigation|May 7, 2024
A mitochondrial surveillance mechanism activated by SRSF2 mutations in hematologic malignanciesXiaolei Liu, Sudhish A Devadiga, Robert F Stanley, et al.
Haematologica|March 10, 2018
Dexamethasone in hyperleukocytic acute myeloid leukemiaSarah Bertoli, Muriel Picard, Emilie Bérard, et al.
Blood|June 2, 2021
Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemiaCaroline Duault, Anil Kumar, Adeleh Taghi Khani, et al.
Blood|September 7, 2007
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsMonica L Guzman, Randall M Rossi, Sundar Neelakantan, et al.
Cancer Cell|February 23, 2010
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutaratePatrick S Ward, Jay Patel, David R Wise, et al.
Leukemia|January 5, 2024
FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemiaPamela J Sung, Murugan Selvam, Simone S Riedel, et al.
Plos One|October 26, 2020
Targeted detection and quantitation of histone modifications from 1,000 cellsNebiyu A Abshiru, Jacek W Sikora, Jeannie M Camarillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemiaDonald E Tsai, Selina M Luger, Charalambos Andreadis, et al.
Cancer Discovery|January 27, 2021
Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML RecurrenceCihangir Duy, Meng Li, Matt Teater, et al.
European Journal of Haematology|December 27, 2024
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based RegimenMargaret Rowe, Daria Babushok, Martin Carroll, et al.
Pageof 13